{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:53:16Z","timestamp":1792857196973,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01CA247769"],"award-info":[{"award-number":["5R01CA247769"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD023611"],"award-info":[{"award-number":["S10OD023611"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00259-024-06754-2","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:01:28Z","timestamp":1716249688000},"page":"3322-3333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-0151","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-3387","authenticated-orcid":false,"given":"Xinrui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4904-332X","authenticated-orcid":false,"given":"Muyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanguang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German Oscar Fonseca","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-4233","authenticated-orcid":false,"given":"Xuedan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3528-5603","authenticated-orcid":false,"given":"Zhanhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-6233","authenticated-orcid":false,"given":"Jin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-0298","authenticated-orcid":false,"given":"Zibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"6754_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.21037\/tlcr.2018.05.06","volume":"7","author":"PM de Groot","year":"2018","unstructured":"de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7:220\u201333.","journal-title":"Transl Lung Cancer Res"},{"key":"6754_CR2","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA: A Cancer Journal for Clinicians. 2021;71:7\u201333.","DOI":"10.3322\/caac.21654"},{"key":"6754_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature11558","volume":"490","author":"JF White","year":"2012","unstructured":"White JF, Noinaj N, Shibata Y, et al. Structure of the agonist-bound neurotensin receptor. Nature. 2012;490:508\u201313.","journal-title":"Nature"},{"key":"6754_CR4","first-page":"184","volume":"3","author":"Z Wu","year":"2012","unstructured":"Wu Z, Martinez-Fong D, Tr\u00e9daniel J, Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne). 2012;3:184.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6754_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/bjc.1984.160","volume":"50","author":"M Goedert","year":"1984","unstructured":"Goedert M, Reeve JG, Emson PC, Bleehen NM. Neurotensin in human small cell lung carcinoma. Br J Cancer. 1984;50:179\u201383.","journal-title":"Br J Cancer"},{"key":"6754_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","volume":"20","author":"JP Vincent","year":"1999","unstructured":"Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302\u20139.","journal-title":"Trends Pharmacol Sci"},{"key":"6754_CR7","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.peptides.2006.04.026","volume":"27","author":"J Mazella","year":"2006","unstructured":"Mazella J, Vincent J-P. Functional roles of the NTS2 and NTS3 receptors. Peptides. 2006;27:2469\u201375.","journal-title":"Peptides"},{"key":"6754_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0039-6060(98)70126-6","volume":"124","author":"RA Ehlers","year":"1998","unstructured":"Ehlers RA, Bonnor RM, Wang X, Hellmich MR, Evers BM. Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery. 1998;124:239\u201347.","journal-title":"Surgery"},{"key":"6754_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1006\/bbrc.2000.2335","volume":"269","author":"RA Ehlers","year":"2000","unstructured":"Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun. 2000;269:704\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"6754_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/ijc.22407","volume":"120","author":"D Zhao","year":"2007","unstructured":"Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C. Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells. Int J Cancer. 2007;120:1652\u20136.","journal-title":"Int J Cancer"},{"key":"6754_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-03245-8","volume":"11","author":"N Christou","year":"2020","unstructured":"Christou N, Blondy S, David V, et al. Neurotensin pathway in digestive cancers and clinical applications: an overview. Cell Death Dis. 2020;11:1\u201312.","journal-title":"Cell Death Dis"},{"key":"6754_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/1440-1681.12787","volume":"44","author":"Q Ouyang","year":"2017","unstructured":"Ouyang Q, Zhou J, Yang W, Cui H, Xu M, Yi L. Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin Exp Pharmacol Physiol. 2017;44:841\u20136.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"6754_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.biochi.2011.04.024","volume":"93","author":"S Dupouy","year":"2011","unstructured":"Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011;93:1369\u201378.","journal-title":"Biochimie"},{"key":"6754_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-5002(00)00248-8","volume":"33","author":"M Ocejo-Garcia","year":"2001","unstructured":"Ocejo-Garcia M, Ahmed SI, Coulson JM, Woll PJ. Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer. 2001;33:1\u20139.","journal-title":"Lung Cancer"},{"key":"6754_CR15","doi-asserted-by":"publisher","first-page":"8252","DOI":"10.18632\/oncotarget.1633","volume":"5","author":"M Younes","year":"2014","unstructured":"Younes M, Wu Z, Dupouy S, et al. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine\/paracrine activation in lung tumors, confirming responsiveness to erlotinib. Oncotarget. 2014;5:8252\u201369.","journal-title":"Oncotarget"},{"key":"6754_CR16","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1158\/1078-0432.CCR-10-0659","volume":"16","author":"M Alifano","year":"2010","unstructured":"Alifano M, Souaz\u00e9 F, Dupouy S, et al. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010;16:4401\u201310.","journal-title":"Clin Cancer Res"},{"key":"6754_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0196-9781(00)00362-4","volume":"22","author":"TW Moody","year":"2001","unstructured":"Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides. 2001;22:109\u201315.","journal-title":"Peptides"},{"key":"6754_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/gut.42.4.546","volume":"42","author":"JC Reubi","year":"1998","unstructured":"Reubi JC, Waser B, Friess H, B\u00fcchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546\u201350.","journal-title":"Gut"},{"key":"6754_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M","volume":"31","author":"L Seethalakshmi","year":"1997","unstructured":"Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate. 1997;31:183\u201392.","journal-title":"Prostate"},{"key":"6754_CR20","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/0008-5472.CAN-06-0450","volume":"66","author":"F Souaz\u00e9","year":"2006","unstructured":"Souaz\u00e9 F, Dupouy S, Viardot-Foucault V, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006;66:6243\u20139.","journal-title":"Cancer Res"},{"key":"6754_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1006\/bbrc.1994.2205","volume":"203","author":"JJ Maoret","year":"1994","unstructured":"Maoret JJ, Pospa\u00ef D, Rouyer-Fessard C, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun. 1994;203:465\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"6754_CR22","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1021\/jm030081k","volume":"46","author":"S Achilefu","year":"2003","unstructured":"Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL. Novel bioactive and Stable Neurotensin Peptide Analogues Capable of Delivering Radiopharmaceuticals and Molecular beacons to tumors. J Med Chem. 2003;46:3403\u201311.","journal-title":"J Med Chem"},{"key":"6754_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0969-8051(01)00284-0","volume":"29","author":"R Bergmann","year":"2002","unstructured":"Bergmann R, Scheunemann M, Heichert C, et al. Biodistribution and catabolism of 18F-labeled neurotensin (8\u201313) analogs. Nucl Med Biol. 2002;29:61\u201372.","journal-title":"Nucl Med Biol"},{"key":"6754_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.nucmedbio.2010.06.011","volume":"38","author":"R Teodoro","year":"2011","unstructured":"Teodoro R, Faintuch BL, N\u00fa\u00f1ez EGF, Queir\u00f3z RG. Neurotensin (8\u201313) analogue: radiolabeling and biological evaluation using different chelators. Nucl Med Biol. 2011;38:113\u201320.","journal-title":"Nucl Med Biol"},{"key":"6754_CR25","first-page":"1649","volume":"44","author":"F Buchegger","year":"2003","unstructured":"Buchegger F, Bonvin F, Kosinski M, et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003;44:1649\u201354.","journal-title":"J Nucl Med"},{"key":"6754_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.nucmedbio.2006.03.003","volume":"33","author":"K Zhang","year":"2006","unstructured":"Zhang K, An R, Gao Z, Zhang Y, Aruva MR. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8\u201313. Nucl Med Biol. 2006;33:505\u201312.","journal-title":"Nucl Med Biol"},{"key":"6754_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00259-008-0894-y","volume":"36","author":"E Garc\u00eda-Garayoa","year":"2009","unstructured":"Garc\u00eda-Garayoa E, Bl\u00e4uenstein P, Blanc A, Maes V, Tourw\u00e9 D, Schubiger PA. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2009;36:37\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6754_CR28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s00259-003-1189-y","volume":"30","author":"M de Visser","year":"2003","unstructured":"de Visser M, Janssen PJJM, Srinivasan A, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6754_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.7150\/thno.7759","volume":"4","author":"Z Wu","year":"2014","unstructured":"Wu Z, Liu S, Nair I, et al. 64Cu labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 receptor expression. Theranostics. 2014;4:770\u20137.","journal-title":"Theranostics"},{"key":"6754_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.2967\/jnumed.114.137489","volume":"55","author":"Z Wu","year":"2014","unstructured":"Wu Z, Li L, Liu S, et al. Facile Preparation of a thiol-reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin receptor-positive tumor. J Nucl Med. 2014;55:1178\u201384.","journal-title":"J Nucl Med"},{"key":"6754_CR31","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1021\/acs.molpharmaceut.5b00325","volume":"12","author":"H Deng","year":"2015","unstructured":"Deng H, Wang H, Wang M, Li Z, Wu Z. Synthesis and evaluation of 64Cu-DOTA-NT-Cy5.5 as a dual-modality PET\/Fluorescence probe to Image Neurotensin receptor-positive tumor. Mol Pharm. 2015;12:3054\u201361.","journal-title":"Mol Pharm"},{"key":"6754_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1021\/bc200078p","volume":"22","author":"F Alshoukr","year":"2011","unstructured":"Alshoukr F, Prignon A, Brans L, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem. 2011;22:1374\u201385.","journal-title":"Bioconjug Chem"},{"key":"6754_CR33","doi-asserted-by":"publisher","first-page":"153601211771136","DOI":"10.1177\/1536012117711369","volume":"16","author":"H Deng","year":"2017","unstructured":"Deng H, Wang H, Zhang H, et al. Imaging neurotensin receptor in prostate Cancer with 64Cu-Labeled neurotensin analogs. Mol Imaging. 2017;16:1536012117711369.","journal-title":"Mol Imaging"},{"key":"6754_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1073\/pnas.90.1.65","volume":"90","author":"D Gully","year":"1993","unstructured":"Gully D, Canton M, Boigegrain R, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A. 1993;90:65\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6754_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1021\/cb900038e","volume":"4","author":"RM Myers","year":"2009","unstructured":"Myers RM, Shearman JW, Kitching MO, Ramos-Montoya A, Neal DE, Ley SV. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem Biol. 2009;4:503\u201325.","journal-title":"ACS Chem Biol"},{"key":"6754_CR36","first-page":"802","volume":"280","author":"D Gully","year":"1997","unstructured":"Gully D, Labeeuw B, Boigegrain R, et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997;280:802\u201312.","journal-title":"J Pharmacol Exp Ther"},{"key":"6754_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0014-2999(97)01510-0","volume":"343","author":"C Betancur","year":"1998","unstructured":"Betancur C, Canton M, Burgos A, et al. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. Eur J Pharmacol. 1998;343:67\u201377.","journal-title":"Eur J Pharmacol"},{"key":"6754_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/00005344-199804000-00012","volume":"31","author":"P Schaeffer","year":"1998","unstructured":"Schaeffer P, Laplace MC, Bernat A, et al. SR142948A is a potent antagonist of the cardiovascular effects of neurotensin. J Cardiovasc Pharmacol. 1998;31:545\u201350.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6754_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2967\/jnumed.117.193847","volume":"59","author":"RP Baum","year":"2018","unstructured":"Baum RP, Singh A, Schuchardt C, et al. 177Lu-3BP-227 for Neurotensin receptor 1\u2013Targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J Nucl Med. 2018;59:809\u201314.","journal-title":"J Nucl Med"},{"key":"6754_CR40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2967\/jnumed.116.185140","volume":"58","author":"J Schulz","year":"2017","unstructured":"Schulz J, Rohracker M, Stiebler M, et al. Proof of therapeutic efficacy of a 177Lu-Labeled neurotensin receptor 1 antagonist in a Colon carcinoma xenograft model. J Nucl Med. 2017;58:936\u201341.","journal-title":"J Nucl Med"},{"key":"6754_CR41","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.2967\/jnumed.115.170530","volume":"57","author":"J Schulz","year":"2016","unstructured":"Schulz J, Rohracker M, Stiebler M, et al. Comparative evaluation of the Biodistribution profiles of a series of Nonpeptidic Neurotensin Receptor-1 antagonists reveals a promising candidate for Theranostic Applications. J Nucl Med. 2016;57:1120\u20133.","journal-title":"J Nucl Med"},{"key":"6754_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1089\/cbr.2010.0952","volume":"26","author":"M Gabriel","year":"2011","unstructured":"Gabriel M, Decristoforo C, W\u00f6ll E, et al. [99mTc]demotensin VI: Biodistribution and initial clinical results in Tumor patients of a Pilot\/Phase I study. Cancer Biotherapy Radiopharmaceuticals. 2011;26:557\u201363.","journal-title":"Cancer Biotherapy Radiopharmaceuticals"},{"key":"6754_CR43","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1021\/jm401491e","volume":"56","author":"C Lang","year":"2013","unstructured":"Lang C, Maschauer S, H\u00fcbner H, Gmeiner P, Prante O. Synthesis and evaluation of a 18F-Labeled diarylpyrazole glycoconjugate for the imaging of NTS1-Positive tumors. J Med Chem. 2013;56:9361\u20135.","journal-title":"J Med Chem"},{"key":"6754_CR44","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1021\/acs.jmedchem.1c00523","volume":"64","author":"E Renard","year":"2021","unstructured":"Renard E, Moreau M, Bellaye P-S, et al. Positron Emission Tomography Imaging of Neurotensin Receptor-Positive Tumors with 68Ga-Labeled antagonists: the Chelate makes the difference again. J Med Chem. 2021;64:8564\u201378.","journal-title":"J Med Chem"},{"key":"6754_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1021\/acs.molpharmaceut.1c00743","volume":"19","author":"T Zhang","year":"2022","unstructured":"Zhang T, Cai J, Xu M, et al. Development of 18F-Labeled vinyl Sulfone\u2013PSMAi conjugates as new PET agents for prostate Cancer imaging. Mol Pharm. 2022;19:720\u20137.","journal-title":"Mol Pharm"},{"key":"6754_CR46","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1021\/acs.bioconjchem.0c00487","volume":"31","author":"T Zhang","year":"2020","unstructured":"Zhang T, Cai J, Wang H, et al. RXH-Reactive 18F-Vinyl sulfones as Versatile agents for PET Probe Construction. Bioconjug Chem. 2020;31:2482\u20137.","journal-title":"Bioconjug Chem"},{"key":"6754_CR47","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1021\/bc200132t","volume":"22","author":"Z Wu","year":"2011","unstructured":"Wu Z, Todorov I, Li L, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor. Bioconjug Chem. 2011;22:1587\u201394.","journal-title":"Bioconjug Chem"},{"key":"6754_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12951-021-01018-9","volume":"19","author":"X Ma","year":"2021","unstructured":"Ma X, Lee C, Zhang T, et al. Image-guided selection of Gd@C-dots as sensitizers to improve radiotherapy of non-small cell lung cancer. J Nanobiotechnol. 2021;19:284.","journal-title":"J Nanobiotechnol"},{"key":"6754_CR49","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1021\/acs.bioconjchem.2c00427","volume":"33","author":"M Li","year":"2022","unstructured":"Li M, Ma X, Molnar CJ, et al. Modular PET Agent Construction Strategy through strain-promoted double-click reagent with efficient photoclick step. Bioconjug Chem. 2022;33:2088\u201396.","journal-title":"Bioconjug Chem"},{"key":"6754_CR50","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/humrep\/deaa177","volume":"35","author":"A Maclean","year":"2020","unstructured":"Maclean A, Bunni E, Makrydima S, et al. Fallopian tube epithelial cells express androgen receptor and have a distinct hormonal responsiveness when compared with endometrial epithelium. Hum Reprod. 2020;35:2097\u2013106.","journal-title":"Hum Reprod"},{"key":"6754_CR51","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41379-019-0285-x","volume":"32","author":"S Dogan","year":"2019","unstructured":"Dogan S, Vasudevaraja V, Xu B, et al. DNA methylation-based classification of sinonasal undifferentiated carcinoma. Mod Pathol. 2019;32:1447\u201359.","journal-title":"Mod Pathol"},{"key":"6754_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane Antigen Heterogeneity and DNA repair defects in prostate Cancer. Eur Urol. 2019;76:469\u201378.","journal-title":"Eur Urol"},{"key":"6754_CR53","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","volume":"14","author":"R Guo","year":"2019","unstructured":"Guo R, Berry LD, Aisner DL, et al. MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019;14:1666\u201371.","journal-title":"J Thorac Oncol"},{"key":"6754_CR54","doi-asserted-by":"publisher","first-page":"10561","DOI":"10.1021\/ja001295j","volume":"122","author":"EH Wong","year":"2000","unstructured":"Wong EH, Weisman GR, Hill DC, et al. Synthesis and characterization of Cross-bridged Cyclams and Pendant-Armed derivatives and structural studies of their copper(II) complexes. J Am Chem Soc. 2000;122:10561\u201372.","journal-title":"J Am Chem Soc"},{"key":"6754_CR55","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ja00179a067","volume":"112","author":"GR Weisman","year":"1990","unstructured":"Weisman GR, Rogers ME, Wong EH, Jasinski JP, Paight ES. Cross-bridged cyclam. Protonation and lithium cation (Li+) complexation in a diamond-lattice cleft. J Am Chem Soc. 1990;112:8604\u20135.","journal-title":"J Am Chem Soc"},{"key":"6754_CR56","doi-asserted-by":"crossref","unstructured":"Weisman GR, Wong EH, Hill DC, Rogers ME, Reed DP, Calabrese JC. Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands. Chem Commun. 1996:947\u20138.","DOI":"10.1039\/cc9960000947"},{"key":"6754_CR57","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2967\/jnumed.111.087700","volume":"52","author":"RA Dumont","year":"2011","unstructured":"Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of \u03b1(\u03bd)\u03b2(3) integrin expression and facile radiosynthesis. J Nucl Med. 2011;52:1276\u201384.","journal-title":"J Nucl Med"},{"key":"6754_CR58","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.1158\/1078-0432.CCR-04-1084","volume":"10","author":"JE Sprague","year":"2004","unstructured":"Sprague JE, Peng Y, Sun X, et al. Preparation and Biological evaluation of Copper-64\u2013Labeled Tyr3-Octreotate using a Cross-bridged Macrocyclic Chelator. Clin Cancer Res. 2004;10:8674\u201382.","journal-title":"Clin Cancer Res"},{"key":"6754_CR59","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1021\/jm401921j","volume":"57","author":"SR Banerjee","year":"2014","unstructured":"Banerjee SR, Pullambhatla M, Foss CA, et al. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;57:2657\u201369.","journal-title":"J Med Chem"},{"key":"6754_CR60","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7150\/thno.7324","volume":"4","author":"G Wieser","year":"2014","unstructured":"Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist\u2013from mice to men. Theranostics. 2014;4:412\u20139.","journal-title":"Theranostics"},{"key":"6754_CR61","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2310\/7290.2009.00015","volume":"8","author":"SH Hausner","year":"2009","unstructured":"Hausner SH, Kukis DL, Gagnon MKJ, et al. Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted Positron Emission Tomography with an \u03b1v\u03b26-Specific peptide. Mol Imaging. 2009;8:111\u201321.","journal-title":"Mol Imaging"},{"key":"6754_CR62","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.nucmedbio.2008.12.008","volume":"36","author":"L Wei","year":"2009","unstructured":"Wei L, Ye Y, Wadas TJ, et al. 64Cu-Labeled CB-TE2A and Diamsar conjugated RGD peptide analogs for Targeting Angiogenesis: comparison of their biological activity. Nucl Med Biol. 2009;36:277\u201385.","journal-title":"Nucl Med Biol"},{"key":"6754_CR63","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1021\/ic990491s","volume":"38","author":"TJ Hubin","year":"1999","unstructured":"Hubin TJ, McCormick JM, Alcock NW, Clase HJ, Busch DH. Crystallographic characterization of stepwise changes in Ligand Conformations as their internal topology changes and two Novel Cross-bridged Tetraazamacrocyclic copper(II) complexes. Inorg Chem. 1999;38:4435\u201346.","journal-title":"Inorg Chem"},{"key":"6754_CR64","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1021\/jm0103817","volume":"45","author":"X Sun","year":"2002","unstructured":"Sun X, Wuest M, Weisman GR, et al. Radiolabeling and in vivo behavior of copper-64-Labeled Cross-bridged Cyclam Ligands. J Med Chem. 2002;45:469\u201377.","journal-title":"J Med Chem"},{"key":"6754_CR65","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2967\/jnumed.107.039487","volume":"48","author":"JC Garrison","year":"2007","unstructured":"Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET\/CT of a prostate Cancer Mouse Model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA Chelation systems. J Nucl Med. 2007;48:1327\u201337.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06754-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06754-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06754-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T14:03:11Z","timestamp":1725285791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06754-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["6754"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06754-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki or comparable ethical standards. All animal experiments were conducted in accordance with the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee (Protocol No. 20\u2013122.0). The analysis of patient data was approved by the Clinical Research Academic Committee of Nanjing Drum Tower Hospital (permit 2023-309-02). Informed consent was obtained from all individual participants included in the study. The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have consented to the publication of the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A patent (No. PCT\/US2023\/066537)\u00a0has been filed related to this project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}